[LTRN Webinar] Lantern Pharma Webinar Wednesdays - Childhood Cancer Awareness Month

Panna Sharma, CEO and President of Lantern Pharma and Dr. Reggie Ewesuedo, Vice president of Clinical Development of Lantern Pharma talks about the recent announcement of our drug candidate, LP-184, receiving three additional rare pediatric disease designation in ultra-rare children’s cancers and Lantern Pharma’s continuous effort to develop a new treatment options for childhood cancers.

0:00 Introduction
1:51 Overview of childhood cancers
3:05 Three additional FDA Rare Pediatric Disease Designation
5:20 Overview- Malignant Rhabdoid Tumor
10:45 Overview- Rhabdomyosarcoma
15:05 Overview- Hepatoblastoma
20:20 LP-184 in rare pediatric cancers - Preclinical results
21:00 MRT Preclinical Results
23:00 ATRT Preclinical Results
24:17 Rhabdomyosarcoma Preclinical Results
25:07 Hepatoblastoma Preclinical Results
26:50 Q&A